NASDAQ:TCDA Tricida (TCDA) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free TCDA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.11▼$0.1952-Week Range N/AVolume31.13 million shsAverage Volume17.62 million shsMarket Capitalization$6.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tricida alerts: Email Address Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Tricida Stock (NASDAQ:TCDA)Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.Read More Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. TCDA Stock News HeadlinesFebruary 6, 2024 | finance.yahoo.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaJanuary 13, 2024 | es.investing.comTricida Inc (TCDAQ)May 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.February 14, 2023 | finance.yahoo.comTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 3, 2023 | wsj.comFirm Retention Summary: Tricida Inc.November 15, 2022 | finance.yahoo.comTricida Announces Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comTricida Provides Strategic UpdateOctober 25, 2022 | markets.businessinsider.comWhy Tricida Stock Is Tanking TodayMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.October 25, 2022 | bizjournals.comFailed trial sends Peninsula kidney drug company's stock tumbling 94%October 25, 2022 | msn.comThis Biotech Lost 95% in a Single Day. It Still Deserves CreditOctober 25, 2022 | finance.yahoo.comTricida Shares Nosedive After Disappointing Data From Much Anticipated Kidney Disease TrialOctober 24, 2022 | investorplace.comWhy Is Tricida (TCDA) Stock Down 90% Today?October 24, 2022 | finance.yahoo.comTricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of VeverimerOctober 19, 2022 | seekingalpha.comTricida announces $125M debt facility - Seeking AlphaOctober 19, 2022 | seekingalpha.comTricida enters $125M debt facility (NASDAQ:TCDA) - Seeking AlphaOctober 19, 2022 | benzinga.comTricida Whale Trades For October 19 - Tricida (NASDAQ:TCDA) - BenzingaOctober 19, 2022 | businesswire.comTricida Announces $125 Million Debt Facility with Hercules Capital - Business WireOctober 18, 2022 | benzinga.com$2 Million Bet On Tricida? 3 Stocks Insiders Are Buying - Tricida (NASDAQ:TCDA), Riley Exploration Permia - BenzingaOctober 14, 2022 | businesswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm - Business WireOctober 13, 2022 | stockhouse.com2022-10-13 | NDAQ:TCDA | Press Release | Tricida Inc. - StockhouseOctober 13, 2022 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Te - BenzingaOctober 7, 2022 | benzinga.comTricida Whale Trades SpottedOctober 4, 2022 | uk.investing.com$17 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UKOctober 3, 2022 | finance.yahoo.comTricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022October 3, 2022 | businesswire.comTricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022 - Business WireSeptember 29, 2022 | uk.investing.comOver $352 Million Bet On Occidental Petroleum? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UKSee More Headlines Receive TCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TCDA CUSIPN/A CIK1595585 Webwww.tricida.com Phone(415) 429-7800FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,570,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-103.81% Debt Debt-to-Equity RatioN/A Current Ratio4.87 Quick Ratio4.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares55,670,000Free Float35,851,000Market Cap$6.01 million OptionableNot Optionable Beta0.22 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesGerrit KlaernerPresident, Chief Executive Officer & DirectorGeoffrey M. ParkerChief Operating & Financial Officer, Executive VPDawn ParsellExecutive Vice President-Clinical DevelopmentRobert McKagueChief Compliance Officer, EVP & General CounselAnnie YoshiyamaChief Accounting Officer & Vice President-FinanceKey CompetitorsHoth TherapeuticsNASDAQ:HOTHKintara TherapeuticsNASDAQ:KTRAProtagenic TherapeuticsNASDAQ:PTIXYumanity TherapeuticsNASDAQ:YMTXKinetaNASDAQ:KAView All Competitors TCDA Stock Analysis - Frequently Asked Questions How were Tricida's earnings last quarter? Tricida, Inc. (NASDAQ:TCDA) posted its earnings results on Monday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09. During the same period in the prior year, the business posted ($1.55) EPS. What is Gerrit Klaerner's approval rating as Tricida's CEO? 2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Tricida own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T). When did Tricida IPO? Tricida (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO. This page (NASDAQ:TCDA) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetry$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBill Gates is all about this tiny $2 stockTimothy SykesNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tricida, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
